Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetrabenazine on Stroop Interference in Huntington Disease
NCT01834911Phase 4Completed
- Sponsor
- New York Medical College
- Start
- Mar 2013
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tetrabenazine in Huntington's disease (HD), sponsored by New York Medical College. Primary endpoint: Stroop Interference at 72 hours. Started Mar 2013; status: completed.
02
Drugs
tetrabenazine
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT01834911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01834911.